TMDX — Stock Film
STOCK FILMSCENE 1/10TMDX · $85.04
Stock Expert AI presents
TMDX
TransMedics Group, Inc
~5 min film100% real numbersplain English
WHAT DOES THIS COMPANY DO?
TransMedics Group, Inc. What it actually does.

Develop and commercialize the Organ Care System (OCS) for organ preservation. Offer OCS LUNG for preserving standard criteria donor lungs. Now — the numbers.

on the stock market since 2019
898 employees
$2.9B market value
WHERE DOES THE MONEY COME FROM?
62%Products
ProductsService Revenue 38%
62% of all revenue comes from a single line: Products.

That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.

Revenue last year:
$605.5M
The net profit left over:
$190.3M
Out of every $100 in sales, $31 stays as net profit.
THE SLICE THAT TURNS INTO PROFIT: 31%

This is an established company with proven profits.

THE SALES TREND
Sales are growing, year after year.

Average growth of 111% a year over the last 4 years. Red columns mark years that ended in a loss.

$30.3M
2021
2022
2023
2024
$605.5M
2025
INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
89
very strong

Profit power and business quality lead the class.

FINANCIAL STRENGTH
21
very weak

Clearly below the class average.

VALUATION
46
weak

Clearly below the class average.

GROWTH
100
very strong

Sales are growing strongly for its sector.

PRICE MOMENTUM
39
weak

Clearly below the class average.

WORTH WATCHING

Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

THE FIVE-YEAR JOURNEY
Below the peak, but no collapse.

The stock trades 52% below its peak. The market has trimmed its expectations for the company.

1
THE BRIGHT SIDE · 1/3
A fat profit margin

The net profit margin is 31% — that slice of every sale is the company’s cushion in hard quarters.

2
THE BRIGHT SIDE · 2/3
Sales keep climbing

Over the last 4 years, sales grew about 111% a year on average.

3
THE BRIGHT SIDE · 3/3
Executives are buying their own stock

Over the last 12 months, company executives reported 25 buys and 20 sells. Management buying with its own money is usually read as a good sign.

1
THE RISKS · 1/3
A thin financial cushion

The balance sheet offers little cushion against a rough stretch. Report-card grade: 21/100.

2
THE RISKS · 2/3
The stock has lost its spark

Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 39/100. For a turnaround signal, the stock first needs to close the gap with the market.

3
THE RISKS · 3/3
The price runs ahead of the earnings

Today’s price already includes part of tomorrow’s optimism. Report-card grade: 46/100.

FINALE · THE GRADE
A
76 / 100 · MoonshotScore

On our five-subject report card, TMDX sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.

The takeaway: TMDX is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Sep 11, 2026 · stockexpertai.com · Stock Film